Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2009 / Cilt: 19 - Sayı: 2

Kardiyak cerrahi sonrası CA 125 belirtecinin kullanımı

Justification for the use of CA 125 levels after cardiac surgery

Pages
82–87
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although CA 125 can be considered a reliable tumor marker in the diagnosis and follow up of patients with malignant diseases, the presence of a recent cardiac surgery with cardiopulmonary bypass must be taken into account when asking for the cause of elevated CA 125 plasma level.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:CA 125, a tumor marker has been found to be elevated in malign conditions as well as in some benign conditions like heart failure.
📊
Key Findings & Data:In this study, we investigated alterations in serum levels of CA 125 during cardiac surgery with cardiopulmonary by-pass.
💡
Conclusion & Impact:Although CA 125 can be considered a reliable tumor marker in the diagnosis and follow up of patients with malignant diseases, the presence of a recent cardiac surgery with cardiopulmonary bypass must be taken into account when asking for the cause of elevated CA 125 plasma level.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kardiyopulmoner bypass · İleriye dönük çalışma · Kalp cerrahi işlemleri

Abstract

CA 125, a tumor marker has been found to be elevated in malign conditions as well as in some benign conditions like heart failure. Cardiac surgery has been shown to cause a systemic inflammatory response. In this study, we investigated alterations in serum levels of CA 125 during cardiac surgery with cardiopulmonary by-pass. Thirty nine patients with a mean age of 54.7 years who underwent either coronary bypass surgery or valvular heart surgery were prospectively recruited to the study. We measured plasma levels of CA 125 preoperatively and on postoperative days 1 and 7. Comparing with preoperative values, CA 125 levels were similar on postoperative day 1 (5.26 [6.89] U/ml vs 5.74 [4.54] U/ml) but elevated significantly on postoperative day 7 (42.1 [34] U/ml, p< 0.0001) (data in median interquantile range). CA 125 levels were found to be elevated after cardiac surgery. The elevations are more in patients undergoing valvular heart surgery than coronary bypass graft surgery. Although CA 125 can be considered a reliable tumor marker in the diagnosis and follow up of patients with malignant diseases, the presence of a recent cardiac surgery with cardiopulmonary bypass must be taken into account when asking for the cause of elevated CA 125 plasma level.

Özet

Bir tümör belirteci olarak bilinen CA 125’in, malign hastalıkların yanısıra kalp yetmezliği gibi bazı benign durumlarda da yükseldiği bildirilmiştir. Kalp cerrahisi sistemik iltihabi bir cevap oluşturur. Çalışmamızda kardiyopulmoner bypass kullanılarak gerçekleştirilen kalp cerrahisinde plazma CA125 düzeylerindeki değişimleri araştırdık. Koroner baypass veya kapak cerrahisi planlanan ve yaş ortalaması 54.7 olan 39 hasta çalışmaya prospektif olarak dahil edildi. Preoperatif dönemde, postoperatif 1. ve 7. günlerde plazma CA 125 seviyesi için kan örnekleri alındı. Preoperatif dönem ve postoperatif 1. günde CA 125 düzeyleri benzer bulundu (5.26 [6.89] U/ml’ye 5.74 [4.54] U/ml). Postoperatif 7. günde ise bazal düzeylere göre anlamlı olarak yükseldi (42.1 [34] Ü/ml, p < 0.0001). CA125 seviyelerinde kapak cerrahisi yapılan hastalarda koroner cerrahisi geçiren hastalara göre daha belirgin artış tespit edildi. CA 125, malign hastalıkların teşhis ve takibinde güvenilir bir tümör belirteci olmakla birlikte, yüksek CA 125 tespit edilen hastalarda yakın zamanda kardiyopulmoner baypass kullanılarak geçirilmiş kalp cerrahisi sorgulanmalıdır.

🔖

Cite This Article

PEKER, R. O., PEKER, T. T., VAROL, E., ÖZAYDIN, M., GÜLMEN, Ş., GÖKALP, O., KAYA, S., KAPAN, Ş., ERDOĞAN, D., SÜTÇÜ, R., ÖCAL, A. (2009). Kardiyak cerrahi sonrası CA 125 belirtecinin kullanımı. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 19 - Sayı: 2, 82–87. https://ajindex.com/articles/323213

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sevinc A, Camci C, Turk HM, et al. How to interpret serum CA125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65: 1-6, 2003
  2. D A’loia A, Faggiano P, Aurigemma G. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure. Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities and short-term prognosis. J Am Coll Cardiol 41: 1805-1811, 2003
  3. Nägele H, Bahlu M, Klapdor R, et al. CA 125 and its relation to cardiac function. Am Heart J 137: 1044-1049, 1999
  4. Faggiano P, D A’loia A, Brentana L. Serum levels of different tumour markers in patients with chronic heart failure. Eur J Heart Fail 7: 57-61, 2005
  5. Kouris NT, Zacharos ID, Kontogianni DD. The significance of CA 125 levels in patients with congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7: 199-203, 2005
  6. Varol E, Ozaydin M, Dogan A, et al. Tumour marker levels in patients with chronic heart failure. Eur J Heart Fail 7: 840-843, 2005
  7. Turk HM, Pekdemir H, Buyukberber S. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumor Biol 24: 172-175, 2003
  8. Battaloglu B, Kaya E, Erdil N, et al. Does cardiopulmonary bypass alter plasma level of tumor markers? CA 125 and carcinoembryonic antigen. Thorac Cardiovasc Surg 50: 201-203, 2002
  9. Downing SW, Edmunds L. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 54: 1236-1243, 1992
  10. Sevinc A, Buyukberber S, Sari R, et al. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 77: 254-257, 2000
  11. Nunez J, Nunez E, Consuegra L, et al. Carbohydrate antigen 125: an emerging prognostic risk factor in acute heart failure? Heart 93: 716- 721, 2007
  12. Diegeler A, Tarnok A, Rauch T. Changes of leukocyte subsets in coronary artery bypass surgery: Cardiopulmonary bypass versus offpump tecniques. Thorac Cardiovasc Surg. 46: 327-332, 1998
  13. Fransen EJ, Maessen JG, Hermens WT, et al. Periopeative myocardial tissue injury and the release of inflammatory mediators in coronary artery bypass graft patients. Cardiovasc Res 45: 853-859, 2000
  14. Zeimet AG, Offner FA, Marth C. Modulation of CA125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res 17: 3129-3131, 1997
  15. Kosar F, Aksoy Y, Ozguntekin G, et al. Relationship between cyt